SBC-110736 | CAS#1629166-02-4 | PCSK9 inhibitor

MedKoo Cat#: 561611 | Name: SBC-110736

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SBC-110736 is a novel inhibitor of proprotein convertase subtilisin kexin type 9 (PCSK9), and has been shown to lower cholesterol levels in mice.

Chemical Structure

SBC-110736

CAS#1629166-02-4

Theoretical Analysis

MedKoo Cat#: 561611

Name: SBC-110736

CAS#: 1629166-02-4

Chemical Formula: C26H27N3O2

Exact Mass: 413.2103

Molecular Weight: 413.52

Elemental Analysis: C, 75.52; H, 6.58; N, 10.16; O, 7.74

Price and Availability

Size	Price	Availability
10mg	USD 150.00	Ready to ship
25mg	USD 250.00	Ready to ship
50mg	USD 450.00	Ready to ship
100mg	USD 750.00	Ready to ship
200mg	USD 1,350.00	Ready to ship
500mg	USD 2,850.00	Ready to ship
1g	USD 3,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SBC-110736; SBC 110736; SBC110736;

IUPAC/Chemical Name

N-[4-(2-Phenyl-4-p-tolyl-piperazine-1-carbonyl)-phenyl]-acetamide

InChi Key

PILMFSWQYWYOJC-UHFFFAOYSA-N

InChi Code

InChI=1S/C26H27N3O2/c1-19-8-14-24(15-9-19)28-16-17-29(25(18-28)21-6-4-3-5-7-21)26(31)22-10-12-23(13-11-22)27-20(2)30/h3-15,25H,16-18H2,1-2H3,(H,27,30)

SMILES Code

CC(NC1=CC=C(C(N2C(C3=CC=CC=C3)CN(C4=CC=C(C)C=C4)CC2)=O)C=C1)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#T21D10P09

QC Data

View QC data: current batch, Lot#T21D10P09

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

SBC-110736 is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor.

In vitro activity:

To be determined

In vivo activity:

Inhibition of PCSK9 by SBC-110736 could potentially serve as a therapeutic strategy for mitigating UVB-induced skin damage. This mouse model of UVB-induced skin damange revealed that UVB exposure significantly increased PCSK9 expression in skin, but SBC-110736 treatment ameliorated skin damage, epidermal thickness increase, and keratinocyte hyperproliferation caused by UVB exposure. Reference: J Biol Chem. 2023 Jul;299(7):104895. https://pubmed.ncbi.nlm.nih.gov/37290532/

	Solvent	mg/mL	mM
Solubility
	Soluble in DMSO	64.0	154.77

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 413.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Luan C, He Y, Liu W, Rong Y, Gao J, Xu K, Yu H, Hu Y, Zhang J, Chen K, Guo W. PCSK9 inhibition interrupts the cross-talk between keratinocytes and macrophages and prevents UVB-induced skin damage. J Biol Chem. 2023 Jul;299(7):104895. doi: 10.1016/j.jbc.2023.104895. Epub 2023 Jun 6. PMID: 37290532; PMCID: PMC10331474.

In vitro protocol:

To be determined

In vivo protocol:

Lavecchia, A., & Cerchia, C. (2019). Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy. Future medicinal chemistry, 11(5), 423-441.